Khan pushes on with Biota board bid
20 February, 2003 by Pete YoungThe largest shareholder in drug developer Biota Holdings, Perth entrepreneur Farooq Khan, is renewing his bid to force his way onto its board by calling for a March 28 general meeting in Melbourne.
Norwood gets European patent for skin surface laser
18 February, 2003 by Jennie SouthgateThe European Patent Office has granted Norwood Abbey a patent for its laser perforator technology, covering a device and method for the perforation of the skin for draining blood or administering pharmaceuticals.
VIR201 safe but no immune response as yet
17 February, 2003 by Jennie SouthgateFinal results from the initial stage of Virax's Phase I/II study of its lead HIV immune based therapy, VIR201, have shown the drug to be safe but whether it will elicit an immune response is still open to question.
GTG hires US scientist to lead cell sorting project
14 February, 2003 by Melissa TrudingerA Genetic Technologies cell sorting program has been given a boost with the appointment of US scientist Dr Ralph Bohmer, an expert in using flow cytometry for differentiating cells, to lead the project.
Researcher puts the case for cloning in wake of sheep death
14 February, 2003 by Graeme O'NeillThe death of Australia's first cloned sheep, Matilda, is not the only setback in efforts to clone livestock species -- nor will it be the last, says Dr Ian Lewis, program leader with the Cooperative Research Centre for Innovative Dairy Products.
Autogen to get milestone payment from Merck
13 February, 2003 by Melissa TrudingerMelbourne-based biotech Autogen will receive $AUD1.39 million in a milestone payment from commercial partner Merck, the company announced today.
Gardiner Foundation announces R&D funding awards
12 February, 2003 by Melissa TrudingerThe Geoffrey Gardiner Dairy Foundation has announced the inaugural recipients of its major research and development funding initiative.
GroPep says turn-around is on track despite loss
12 February, 2003 by Melissa TrudingerDespite slightly lower than expected revenues for the half-year ending December 31, Adelaide company GroPep was on track for full recovery, said CFO Tony Mitchell today.
New target found in search for Alzheimer's treatment
12 February, 2003 by Graeme O'NeillResearchers hunting the serial murderer responsible for the progressive, mass-death of neurons in Alzheimer's disease, the most common form of dementia, have found a new suspect.
Mad cow just got madder in face of multifaceted molecule
11 February, 2003 by Graeme O'NeillThe story of the so-called prion diseases, including 'mad cow' disease, is one of the strangest in the annals of 20th century medical science -- and it grows stranger still.
Bionomics, JJR arrangement has happy ending
10 February, 2003 by Melissa TrudingerA collaboration between Adelaide company Bionomics and Johnson and Johnson Research (JJR) has been concluded without an ongoing commercial arrangement.
Domantis granted patent, rights on new antibody selection technique
10 February, 2003 by Graeme O'NeillUK-based Domantis, a developer of single-domain antibody therapeutics, has been granted a US patent on a new emulsion technique for selecting antibodies and antibody fragment.
VRI BioMedical names new CEO
07 February, 2003 by Iain ScottPerth-based probiotics and diagnostics company VRI BioMedical has named Dr Peter French as its new CEO.
Our first cloned sheep found dead
07 February, 2003 by Melissa TrudingerMatilda, Australia's first cloned sheep, has died of unknown causes, according to the South Australian Research and Development Institute (SARDI).
Prima touts DCtag success in vaccine development
07 February, 2003 by Graeme O'NeillPrima BioMed subsidiary Panvax has reported that recent trials of its DCtag vaccine technology in sheep have confirmed its potential for developing novel vaccines and immunotherapies for human diseases including cancers, viral infections, malaria and tuberculosis.
